ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.
- Share Purchase Plan offers shares at up to $0.115 or 2.5% VWAP discount
- Plan fully underwritten and capped at $1 million with potential oversubscriptions
- Free attaching options offered subject to shareholder approval
- Funds to support ERP system, patent maintenance, and working capital
- Eligible shareholders in Australia, NZ, UK, and Singapore may participate
Capital Raise Extends ClearVue’s Funding Run
ClearVue Technologies Limited (ASX:CPV) is opening the doors for retail investors to top up their holdings through a $1 million Share Purchase Plan (SPP), following a recent $5 million placement to institutional and professional investors. The SPP offers eligible shareholders the chance to buy shares at a price capped at $0.115 each or at a 2.5% discount to the five-day volume weighted average price (VWAP) before the plan closes, whichever is lower.
This pricing ceiling represents a nearly 20% discount to the $0.1431 VWAP before the plan announcement on 22 June 2026, highlighting ClearVue’s effort to incentivise participation while managing dilution. The plan is fully underwritten by Alpine Capital and SP Corporate Advisory, ensuring that the $1 million target will be met or exceeded, with the company reserving the right to accept oversubscriptions or scale back applications at its discretion.
Options Sweeten the Deal but Await Shareholder Nod
Alongside the shares, participants will be entitled to one free attaching option per share subscribed, exercisable at $0.115 within three years. However, these options are offered under a separate prospectus and require shareholder approval, expected at a general meeting in late August or early September 2026. The options do not form part of the SPP offer document and are not issued under ASIC’s streamlined instrument for share purchase plans.
Broad Eligibility with Geographic Restrictions
The SPP is open to shareholders registered as of 19 June 2026 with addresses in Australia, New Zealand, the United Kingdom, or Singapore. Participation is capped at $30,000 per shareholder within a 12-month period, regardless of multiple holdings or accounts. Custodians and nominees may apply on behalf of eligible beneficiaries, subject to compliance and certification requirements.
Notably, the offer excludes shareholders outside these jurisdictions due to foreign securities laws, and shares issued under the plan will rank equally with existing shares, with quotation on ASX expected shortly after issuance.
Allocation of Funds to Strategic Priorities
ClearVue intends to channel the combined proceeds from the placement and the SPP towards implementing and rolling out its enterprise resource planning (ERP) system, advancing research and development, maintaining and renewing patents, and general working capital needs. These investments align with the company’s ongoing efforts to enhance operational efficiency and protect its intellectual property portfolio.
The board retains discretion to adjust fund allocation depending on emerging circumstances, a standard caveat in capital raising communications.
Oversubscription and Shareholder Control
While the company aims to raise $1 million through the SPP, it reserves the right to accept oversubscriptions or scale back applications equitably. Any shortfall after the SPP will be covered by the underwriters using available placement capacity under ASX Listing Rule 7.1, avoiding the need for further shareholder approval unless capacity is exceeded.
The recent placement, which raised approximately $5 million at the same issue price of $0.115 per share, was completed in two tranches, with some shares and options pending shareholder approval. This coordinated capital raising underscores ClearVue’s strategy to strengthen its balance sheet ahead of scaling operations.
The SPP closes on 13 July 2026, with shares expected to be issued by 20 July and options issued following shareholder approval. Investors should note that share prices may fluctuate between the offer and issue dates, reflecting market dynamics.
Bottom Line?
ClearVue’s SPP complements its recent placement to bolster funds for operational upgrades and IP protection, but investor returns hinge on market reception and approval of attaching options.
Questions in the middle?
- Will shareholder approval for the attaching options be secured without significant opposition?
- How will ClearVue allocate funds if oversubscriptions push the raise beyond $1 million?
- What impact will the new shares and options have on ClearVue’s share price and liquidity post-issue?